-

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Stride, Inc. (LRN)

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Stride, Inc. (“Stride” or the “Company”) (NYSE: LRN). The investigation concerns whether Stride and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

[Click here to learn more about the investigation]

On October 16, 2024, Fuzzy Panda Research published a report on Stride alleging that the Company inflated its earnings by misleading the market about the impact of federal COVID-19 relief funds. According to the report, 25% of the Company’s EBITDA came from Elementary and Secondary School Emergency Relief (ESSER) funds expiring in September 2024. The report also accuses Stride of hiding “ghost students” and failing to disclose schools leaving the Company, alongside allegations of overbilling and fraudulent reimbursement claims. On this news, the price of Stride shares declined by $6.55 per share, or approximately 9.3%, from $70.59 per share on October 15, 2024, to close at $64.04 on October 16, 2024.

If you purchased or otherwise acquired Stride securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

Kirby McInerney LLP

NYSE:LRN

Release Versions
$Cashtags

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.com
investigations@kmllp.com

More News From Kirby McInerney LLP

SPORTRADAR GROUP AG INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Sportradar Group AG (“Sportradar” or the “Company”) (NASDAQ:SRAD). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 22, 2026, Muddy Waters Research published a report alleging, among other things, that Sp...

NANO-X IMAGING LTD. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Nano-X Imaging Ltd. (“Nano-X” or the “Company”) (NASDAQ:NNOX). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] What Happened? On April 20, 2026, Nano-X announced its fourth quarter 2025 financial results. Among other items, Nan...

ALDX INVESTOR REMINDER: Aldeyra Therapeutics, Inc. Investors Have Until May 29, 2026 To Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ:ALDX) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until May 29, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this de...
Back to Newsroom